These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30557991)

  • 1. A scoring system to predict HBsAg seroclearance in hepatitis B and C coinfected patients treated with interferon and ribavirin in an Asian cohort.
    Yen YH; Kee KM; Kuo FY; Chang KC; Hu TH; Lu SN; Wang JH; Hung CH; Chen CH
    Medicine (Baltimore); 2018 Dec; 97(50):e13383. PubMed ID: 30557991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up.
    Yu ML; Lee CM; Chen CL; Chuang WL; Lu SN; Liu CH; Wu SS; Liao LY; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Su WW; Lin CL; Yang HC; Chen PJ; Chen DS; Liu CJ;
    Hepatology; 2013 Jun; 57(6):2135-42. PubMed ID: 23322699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses.
    Yeh ML; Hung CH; Huang JF; Liu CJ; Lee CM; Dai CY; Wang JH; Lin ZY; Lu SN; Hu TH; Yu ML; Kao JH; Chuang WL; Chen PJ; Chen DS
    PLoS One; 2011; 6(6):e20752. PubMed ID: 21695152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection.
    Yeh ML; Huang CF; Huang CI; Holmes JA; Hsieh MH; Tsai YS; Liang PC; Tsai PC; Hsieh MY; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Chung RT; Yu ML
    J Hepatol; 2020 Jul; 73(1):62-71. PubMed ID: 32061869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin.
    Viganò M; Aghemo A; Iavarone M; Rumi MG; Agnelli F; Lampertico P; Donato MF; Colombo M
    Antivir Ther; 2009; 14(6):789-96. PubMed ID: 19812441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa.
    Boyd A; Maylin S; Moh R; Mahjoub N; Gabillard D; Eholié SP; Danel C; Anglaret X; Zoulim F; Girard PM; Delaugerre C; Lacombefor K;
    J Gastroenterol Hepatol; 2016 Mar; 31(3):634-44. PubMed ID: 26313291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precore/core promoter mutations and hepatitis B virus genotype in hepatitis B and C dually infected patients treated with interferon-based therapy.
    Hung CH; Chen CH; Lu SN; Wang JH; Hu TH; Huang CM; Tsai MC; Lee CM
    Antiviral Res; 2012 Jan; 93(1):55-63. PubMed ID: 22061616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
    Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Level of Hepatitis B (HB) Core Antibody Associates With Seroclearance of HBV DNA and HB Surface Antigen in HB e Antigen-Seronegative Patients.
    Hu HH; Liu J; Chang CL; Jen CL; Lee MH; Lu SN; Wang LY; Quan Y; Xia NS; Chen CJ; Chen PJ; Yang HI
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):172-181.e1. PubMed ID: 29753083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus.
    Yu JW; Sun LJ; Zhao YH; Kang P; Gao J; Li SC
    Liver Int; 2009 Nov; 29(10):1485-93. PubMed ID: 19602134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis.
    Liu JY; Sheng YJ; Hu HD; Zhong Q; Wang J; Tong SW; Zhou Z; Zhang DZ; Hu P; Ren H
    Virol J; 2012 Sep; 9():186. PubMed ID: 22950520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term observation on hepatitis B surface antigen seroclearance in therapy experienced HIV/HBV co-infected Chinese.
    Yang R; Gui X; Ke H; Xiong Y; Gao S
    J Viral Hepat; 2020 Feb; 27(2):127-134. PubMed ID: 31571343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients.
    Strassl R; Reiberger T; Honsig C; Payer BA; Mandorfer M; Grabmeier-Pfistershammer K; Rieger A; Kundi M; Grundtner P; Peck-Radosavljevic M; Popow-Kraupp T
    J Viral Hepat; 2014 Jul; 21(7):508-16. PubMed ID: 24112778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
    Liu CJ; Chuang WL; Lee CM; Yu ML; Lu SN; Wu SS; Liao LY; Chen CL; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Liu CH; Su WW; Lin CL; Jeng YM; Chen PJ; Chen DS
    Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection.
    Liu CJ; Chen PJ
    World J Gastroenterol; 2014 Mar; 20(11):2955-61. PubMed ID: 24659886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy of Peg-Interferon/Ribavirin with and without Lamivudine therapy for HBeAg-positive hepatitis B and C dual infection.
    Yeh ML; Hsieh MY; Huang CI; Huang CF; Hsieh MH; Huang JF; Dai CY; Chuang WL; Yu ML
    J Gastroenterol Hepatol; 2016 Apr; 31(4):835-41. PubMed ID: 26478984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient.
    Potthoff A; Deterding K; Trautwein C; Rifai K; Manns MP; Wedemeyer H
    Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):906-9. PubMed ID: 17873617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment Hepatitis B Viral Load Predicts Long-Term Hepatitis B Response After Anti-Hepatitis C Therapy in Hepatitis B/C Dual-Infected Patients.
    Yeh ML; Huang CI; Huang CF; Hsieh MH; Liu TW; Lin YH; Liang PC; Hsieh MY; Lin ZY; Chen SC; Huang JF; Kuo PL; Dai CY; Yu ML; Chuang WL
    J Infect Dis; 2019 Apr; 219(8):1224-1233. PubMed ID: 30452671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
    Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
    Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously.
    Cheng HR; Kao JH; Wu HL; Chen TC; Tseng TC; Liu CH; Su TH; Chen PJ; Chen DS; Liu CJ
    Liver Int; 2014 Jul; 34(6):e71-9. PubMed ID: 24119014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.